Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The investigators' hypothesis is that maternal treatment with Letermovir will inhibit fetal
CMV replication better than Valaciclovir in infected fetuses and lead to a higher proportion
of negative CMV PCR at birth in cord blood.
The main objective is to demonstrate that Letermovir administered to women carrying a CMV
infected fetus following a maternal infection of the first trimester increases the proportion
of neonates with a negative CMV PCR in neonatal blood collected in the first day of life or
in cord blood in case of termination of pregnancy (TOP) compared to Valaciclovir.
In each group , the proportion of asymptomatic neonates and the number and type of long-term
sequelae at 2 years will also be assessed and compared.